US11135172 — Rifabutin-based compositions and methods for treating Helicobacter pylori infection
Method of Use · Assigned to Redhill Biopharma Ltd · Expires 2034-02-12 · 8y remaining
What this patent protects
This patent protects a single oral solid dosage form containing at least two antibiotic agents and a proton pump inhibitor for treating Helicobacter pylori infection.
USPTO Abstract
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
Drugs covered by this patent
- Amoxil (amoxicillin) · Generic (originally Beecham/GSK)
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2660 |
— | Amoxil |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.